Mechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach.
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
received:
19
01
2022
accepted:
03
05
2022
pubmed:
30
6
2022
medline:
2
8
2022
entrez:
29
6
2022
Statut:
ppublish
Résumé
In a large, multiethnic cohort of youths with obesity, we analyzed pathophysiological and genetic mechanisms underlying variations in plasma glucose responses to a 180 min oral glucose tolerance test (OGTT). Latent class trajectory analysis was used to identify various glucose response profiles to a nine-point OGTT in 2,378 participants in the Yale Pathogenesis of Youth-Onset T2D study, of whom 1,190 had available TCF7L2 genotyping and 358 had multiple OGTTs over a 5 year follow-up. Insulin sensitivity, clearance, and β-cell function were estimated by glucose, insulin, and C-peptide modeling. Four latent classes (1 to 4) were identified based on increasing areas under the curve for glucose. Participants in class 3 and 4 had the worst metabolic and genetic risk profiles, featuring impaired insulin sensitivity, clearance, and β-cell function. Model-predicted probability to be classified as class 1 and 4 increased across ages, while insulin sensitivity and clearance showed transient reductions and β-cell function progressively declined. Insulin sensitivity was the strongest determinant of class assignment at enrollment and of the longitudinal change from class 1 and 2 to higher classes. Transitions between classes 3 and 4 were explained only by changes in β-cell glucose sensitivity. We identified four glucose response classes in youths with obesity with different genetic risk profiles and progressive impairment in insulin kinetics and action. Insulin sensitivity was the main determinant in the transition between lower and higher glucose classes across ages. In contrast, transitions between the two worst glucose classes were driven only by β-cell glucose sensitivity.
Identifiants
pubmed: 35766976
pii: 147147
doi: 10.2337/dc22-0110
pmc: PMC9346992
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Glucose
IY9XDZ35W2
Banques de données
figshare
['10.2337/figshare.19859200']
ClinicalTrials.gov
['NCT01967849']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1841-1851Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK114504
Pays : United States
Organisme : NIMHD NIH HHS
ID : R01 MD015974
Pays : United States
Organisme : NICHD NIH HHS
ID : K24 HD001464
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK045735
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD028016
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD040787
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024139
Pays : United States
Organisme : NIDDK NIH HHS
ID : K12 DK094714
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK111038
Pays : United States
Informations de copyright
© 2022 by the American Diabetes Association.
Références
Diabetes Care. 2018 Jan;41(Suppl 1):S152-S153
pubmed: 29222386
Comput Methods Programs Biomed. 1996 Mar;49(2):157-76
pubmed: 8735023
Int J Obes (Lond). 2019 Jul;43(7):1363-1369
pubmed: 30568272
J Clin Endocrinol Metab. 2006 Nov;91(11):4287-94
pubmed: 16912127
PLoS One. 2020 Nov 30;15(11):e0242360
pubmed: 33253307
Diabetes Care. 2020 Nov;43(11):2668-2674
pubmed: 32900788
Diabetes Care. 2020 Oct;43(10):2553-2563
pubmed: 32788279
Diabetes Care. 2017 Aug;40(8):1082-1089
pubmed: 28611053
J Clin Endocrinol Metab. 2020 May 1;105(5):
pubmed: 31996919
Diabetes Care. 2016 Aug;39(8):1431-9
pubmed: 27293201
J Clin Res Pediatr Endocrinol. 2020 Oct 2;13(2):160-169
pubmed: 33006553
Endocrine. 2017 Feb;55(2):427-434
pubmed: 27699707
Diabetes Care. 2021 Sep;44(9):1938-1947
pubmed: 34131048
Diabetes Care. 2006 Jul;29(7):1613-8
pubmed: 16801587
Diabetes. 1992 Mar;41(3):368-77
pubmed: 1551497
J Pediatr Endocrinol Metab. 2000;13 Suppl 6:1385-94
pubmed: 11202214
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2131-2139
pubmed: 30445459
Diabetes Care. 2003 Apr;26(4):1026-33
pubmed: 12663568
JAMA. 2021 Aug 24;326(8):717-727
pubmed: 34427600
Diabetes Obes Metab. 2020 Sep;22(9):1628-1638
pubmed: 32363679
Diabetes Obes Metab. 2019 May;21(5):1191-1198
pubmed: 30663201
Diabetes. 2001 Nov;50(11):2444-50
pubmed: 11679420
Hepatology. 2018 Oct;68(4):1376-1390
pubmed: 29665034
Arch Dis Child. 1969 Jun;44(235):291-303
pubmed: 5785179
Children (Basel). 2020 Dec 04;7(12):
pubmed: 33291552
Eur J Endocrinol. 2012 Jan;166(1):107-14
pubmed: 22009494
Diabetologia. 2020 Jan;63(1):206-218
pubmed: 31676981
Diabetologia. 2015 Jan;58(1):87-97
pubmed: 25292440
Lancet. 2017 Jun 3;389(10085):2252-2260
pubmed: 28589895
Magn Reson Imaging. 1997;15(3):287-93
pubmed: 9201675
Diabetes. 2019 Nov;68(11):2074-2084
pubmed: 31399433
J Clin Endocrinol Metab. 2020 Feb 1;105(2):
pubmed: 31972003
Arch Dis Child. 1970 Feb;45(239):13-23
pubmed: 5440182
Metabolism. 2020 Apr;105:154185
pubmed: 32061908
J Clin Endocrinol Metab. 2004 Mar;89(3):1096-101
pubmed: 15001593
Int J Obes (Lond). 2019 Apr;43(4):673-682
pubmed: 30337653
Stat Methods Med Res. 2014 Feb;23(1):74-90
pubmed: 22517270
Diabetes Obes Metab. 2008 Nov;10 Suppl 4:77-87
pubmed: 18834435
Diabetologia. 2018 Jan;61(1):101-107
pubmed: 28983719
Metabolism. 2017 May;70:42-50
pubmed: 28403944
Diabetes Care. 2018 Aug;41(8):1740-1748
pubmed: 29853473
Diabetes Obes Metab. 2022 Jul;24(7):1267-1276
pubmed: 35297549
Diabetes Metab Res Rev. 2010 May;26(4):280-6
pubmed: 20503260